G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.

about

Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.Cost analysis of a randomized stem cell mobilization study in multiple myeloma.

P2860

Q40081439-00C528E7-5800-4A42-AE61-E5D389926969 Q40490106-FB431AA5-F037-4C99-98C7-90DFD5871FDF Q48130246-C6B712C3-3628-409D-8FF0-98319997A79B

P2860

G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.

Item

http://www.wikidata.org/entity/Q41267193

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

G-CSF plus preemptive plerixaf ...... ess, safety and cost analysis.

@en

type

Item

label

G-CSF plus preemptive plerixaf ...... ess, safety and cost analysis.

@en

prefLabel

G-CSF plus preemptive plerixaf ...... ess, safety and cost analysis.

@en

P1476

G-CSF plus preemptive plerixaf ...... ess, safety and cost analysis.

@en

P2093

A Antar

http://www.w3.org/2001/XMLSchema#string

H A Ghaddara

http://www.w3.org/2001/XMLSchema#string

M A Kharfan-Dabaja

http://www.w3.org/2001/XMLSchema#string

N Kreidieh

http://www.w3.org/2001/XMLSchema#string

R Mahfouz

http://www.w3.org/2001/XMLSchema#string

Z K Otrock

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2008

Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma.

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.

A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.

High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.

Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma.

Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

P2888

bmt.2015.23

P304

813-817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2015.23

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ali Bazarbachi

P577

2015-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273323114

http://www.w3.org/2001/XMLSchema#string

P6179

1043272751

http://www.w3.org/2001/XMLSchema#string

P698

25751646

http://www.w3.org/2001/XMLSchema#string

G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.

about

P2860

P2860

G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698